Terns Pharmaceuticals, Inc.
TERNDelisted May 5, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831363
Terns Pharmaceuticals, Inc. was delisted on May 5, 2026; its insiders filed their last Form 4 on May 5, 2026; 317 institutions reported holding it in 13F filings for Q1 2026, worth $6.56B in total; Soros Fund Management was the only superinvestor holding it.
Q2 2022 vs. Q1 2022
How the institutions holding Terns Pharmaceuticals, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 44 | 2 | 42 | 0 |
| Shares | 16.8M | 22.9K | 14.7M | −2.09M (−12.4%) |
| Value | $50.0M | $68.0K | $36.5M | −$13.5M (−27.0%) |
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held Terns Pharmaceuticals, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ra Capital Management, L.P. | 1,261,435 | $3.13M | 0.08% |
| Ikarian Capital, LLC | 700,000 | $1.74M | 0.72% |
| Affinity Asset Advisors, LLC | 401,268 | $995.0K | 0.54% |
| Armistice Capital, LLC | 323,016 | $801.0K | 0.02% |
| Boothbay Fund Management, LLC | 106,712 | $265.0K | 0.01% |
| Ergoteles LLC | 63,454 | $157.0K | 0.00% |
| Citadel Advisors LLC | 38,810 | $96.0K | 0.00% |
| Bailard, Inc. | 20,300 | $50.0K | 0.00% |
| Acadian Asset Management LLC | 12,627 | $31.0K | 0.00% |
| Qube Research & Technologies Ltd | 11,408 | $28.0K | 0.00% |
| Credit Suisse AG | 7 | $0 | 0.00% |
| Capital Advisors, Ltd. LLC | 102 | $0 | 0.00% |
| PEAK6 Investments LLC | 14,097 | – | – |
Sold out (13)
Institutions that held Terns Pharmaceuticals, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 2,345,959 | $6.97M |
| Cowen and Company, LLC | 85,000 | $252.0K |
| Bank of New York Mellon Corp | 38,059 | $112.0K |
| Charles Schwab Investment Management Inc | 28,746 | $86.0K |
| Nuveen Asset Management, LLC | 14,237 | $43.0K |
| Deutsche Bank AG | 8,033 | $24.0K |
| American International Group, Inc. | 6,811 | $20.0K |
| California State Teachers Retirement System | 5,987 | $18.0K |
| Amalgamated Bank | 2,079 | $6.00K |
| Legal & General Group Plc | 1,454 | $4.00K |
| Royal Bank of Canada | 843 | $3.00K |
| Ameritas Investment Partners, Inc. | 708 | $2.00K |
| Point72 Hong Kong Ltd | 71 | $0 |
Not filed for Q2 2022 yet (2)
Institutions that held Terns Pharmaceuticals, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 20,784 | $62.0K |
| Amalgamated Financial Corp. | 2,079 | $6.00K |